Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2018

View Archived Issues

Cognitive, somatic stabilization by treatment with IgG-IDUA fusion protein in children with MPS I

Aging, ARCH and AML

Specific redox enzyme helps reverse fibrosis

A designer supramolecule AK-750 amplifies innate immune responses in preclinical models of cancer

A mosaic HIV-1 vaccine is assessed in a phase I/IIa trial and in rhesus monkeys

Novel mouse model of miR-7-induced pancreatic beta-cell dedifferentiation

Animal model of HAAF provides insight on pathological process of the disease

Longitudinal study confirms fat, disputes sugar as obesity cause in mice

Rimeporide well tolerated in boys with Duchenne muscular dystrophy

Concentric Analgesics initiates phase II trial of CA-008 to treat postsurgical pain

Promising data presented from completed pivotal study of PRO-140 with HAART for HIV-1

Neurotrope initiates enrollment in confirmatory phase II study of bryostatin-1

RegenxBio initiates first-in-human trial of RGX-111 for treatment of MPS I

Phase III CREDENCE trial of Invokana stopped early due to promising outcomes

Researchers present clinical data for RG-7916 in patients with SMA

Destiny Pharma and Aston University establish biofilm research collaboration

CAPSTONE-2 influenza trial of baloxavir marboxil meets primary objective

Pfizer begins pivotal phase III program for fidanacogene elaparvovec in hemophilia B

Longevity Biotech launches clinical neuroinflammation biomarker study

Spero awarded funding to develop SPR-994

Abbisko Therapeutics patents FGFR-4 inhibitors

Nanjing Carephar Shenghui Pharmaceutical Co. divulges RORgammaT antagonists

Bayer divulges new B1 receptor antagonists

Orion presents CYP11A1 inhibitors

Lundbeck discloses PDE1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...